Search Result

Results for "

replicon

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Dengue virus (1) DNA/RNA Synthesis (6) Drug Metabolite (4) Endogenous Metabolite (4) Enterovirus (4) HBV (2) HCV (48) HCV Protease (5) IFNAR (1) Isotope-Labeled Compounds (4) JAK (1) SARS-CoV (9) STAT (1) Topoisomerase (4)
By Research Areas:	Cancer (1) Infection (50) Inflammation/Immunology (5)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138305

HCV-IN-31

HCV Infection Inflammation/Immunology

HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC₅₀/EC₉₅ of 15.7 μM for HCV replicon .

HCV-IN-31	HCV	Infection Inflammation/Immunology
HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC₅₀/EC₉₅ of 15.7 μM for HCV replicon .

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-10465

Daclatasvir dihydrochloride Maximum Cited Publications 44 Publications Verification BMS-790052 dihydrochloride; EBP 883 dihydrochloride	HCV	Infection
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 µM and 3.27 µM, respectively .

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-N8188

Dehydrojuncusol	HCV HCV Protease	Infection
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35 µM) .

HY-10466

Daclatasvir Maximum Cited Publications 44 Publications Verification BMS-790052; EBP 883	HCV	Infection
Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for *multiple HCV replicon* genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀**s of 1.5 µM and 3.27 µM, respectively .

HY-10118

Filibuvir 2 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .

HY-109035

Inarigivir soproxil 1 Publications Verification SB9200; GS-9992	HCV HBV	Infection
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC₅₀s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .

HY-W063968

RO8191 5+ Cited Publications CDM-3008; RO4948191	IFNAR JAK STAT HCV HBV	Infection
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .

HY-U00213

Furaprofen R803	HCV	Infection
Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC₅₀, ~30 nM) than against the genotype 2a replicon (EC₅₀, ~1,000 nM).

HY-16784

Samatasvir IDX719; IDX18719	HCV HCV Protease	Infection
Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC₅₀s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .

HY-N0620

Mulberroside C

HCV Infection

Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .
HY-111087

AZD-7295

HCV Protease Infection Inflammation/Immunology

AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

Mulberroside C	HCV	Infection
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .

AZD-7295	HCV Protease	Infection Inflammation/Immunology
AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

HY-15005B

Sofosbuvir impurity C	Drug Metabolite	Others
Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0719

Sofosbuvir impurity B	Drug Metabolite	Others
Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0723

Sofosbuvir impurity D	Drug Metabolite	Others
Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-I0727

Sofosbuvir impurity E	Drug Metabolite	Others
Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15602B

Ledipasvir D-tartrate 25+ Cited Publications GS-5885 D-tartrate	HCV	Infection
Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-136267

HCV-IN-30

HCV Infection

HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
HY-10244

MK-0608

HCV Infection

MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC₅₀ of 0.3 μM (EC₉₀=1.3 μM) in the subgenomic-replicon assay .
HY-12732

PTC 725

HCV Infection

PTC 725 is a potent, selective and orally active Hepatitis C Virus NS4B Protein inhibitor. PTC 725 inhibits HCV 1b (Con1) replicons .

HCV-IN-30	HCV	Infection
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

MK-0608	HCV	Infection
MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC₅₀ of 0.3 μM (EC₉₀=1.3 μM) in the subgenomic-replicon assay .

PTC 725	HCV	Infection
PTC 725 is a potent, selective and orally active Hepatitis C Virus NS4B Protein inhibitor. PTC 725 inhibits HCV 1b (Con1) replicons .

HY-10468

NM107 2'-C-Methylcytidine; NM-107	HCV	Infection
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM .

HY-15005S1

Sofosbuvir-d6 PSI-7977-d₆; GS-7977-d₆	HCV	Infection
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15602A

Ledipasvir (acetone) 25+ Cited Publications GS-5885 acetone	HCV	Infection
Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602D

Ledipasvir (diacetone) GS-5885 diacetone	HCV	Infection
Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-157405

DENV-IN-11	Dengue virus	Infection
DENV-IN-11 (SC27), a sulfonamide chalcone, is a potent DENV inhibitor that targeted viral methyltransferase. DENV-IN-11 reduced DENV2 replicon replication. DENV-IN-11 can be used for dengue infection research .

HY-101662

Pibrentasvir ABT-530	HCV	Infection
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC₅₀s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

HY-15005S

Sofosbuvir-13C,d3 PSI-7977-¹³C,d₃; GS-7977-¹³C,d₃	Isotope-Labeled Compounds HCV	Infection
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15005A

PSI-7976	HCV	Infection
PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-147763

HCV-IN-39	HCV	Infection
HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons .

HY-135867

NHC-triphosphate	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-15236

PSI-6206 3 Publications Verification RO 2433; GS-331007	HCV	Infection
PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-15602

Ledipasvir 25+ Cited Publications GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-135867A

NHC-triphosphate tetrasodium	Endogenous Metabolite Enterovirus HCV Topoisomerase	Infection
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-135867E

NHC-triphosphate tetraammonium 5 Publications Verification	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-147764

HCV-IN-40	HCV	Infection
HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons .

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-19921

JTK-853
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-10237

Boceprevir 25+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-146344

Antiviral agent 17	Antibiotic	Infection
Antiviral agent 17 (Compound 4) is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC₅₀ = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus. Antiviral agent 17 has the potential for the research of infectious and malignant diseases .

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-15602S

Ledipasvir-d6 GS-5885-d₆	HCV SARS-CoV	Infection
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-12633

GS-6620	HCV	Inflammation/Immunology
GS-6620 is?potent and selective pangenotype HCV inhibitor against HCV replicons of genotypes 1 to 6 (EC₅₀: 0.048 to 0.68 μM). GS-6620 shows limited activities against other viruses, maintaining only some of its activity against the closely related bovine viral diarrhea virus (EC₅₀, 1.5 μM) .

HY-10237S

Boceprevir-d9 EBP 520-d₉; SCH 503034-d₉	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-125371

2'-C-Methyladenosine 1 Publications Verification	HCV	Infection Inflammation/Immunology
2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC₅₀ values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis .

HY-15236S

PSI-6206-13C,d3 RO-2433-¹³C,d₃; GS-331007-¹³C,d₃; Sofosbuvir metabolite GS-331007-¹³C,d₃	HCV	Infection
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-14391

PSI-353661 GS-558093	HCV	Infection
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC₉₀s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0620

Mulberroside C	Infection Monophenols other families Classification of Application Fields Source classification Phenols Plants Moraceae Disease Research Fields Morus alba Linn.	HCV
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-N8188

Dehydrojuncusol	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	HCV HCV Protease
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35 µM) .

HY-135867

NHC-triphosphate	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-135867A

NHC-triphosphate tetrasodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .

HY-N6798

Myriocin 4 Publications Verification Thermozymocidin; ISP-I	Infection Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	HCV Antibiotic
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 µg/mL for inhibiting HCV infection .

Cat. No.	Product Name	Chemical Structure

HY-15005S1

Sofosbuvir-d6
Sofosbuvir-d₆ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-15236S

PSI-6206-13C,d3
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-15005S

Sofosbuvir-13C,d3
Sofosbuvir- ¹³C,d₃ is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

replicon

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products